Abstract
Aim: To determine whether or not a decoction made from Qigu Zhushui has a suppressive
impact on malignant ascites in mice.
Background: Malignant ascites are one of the common complications of advanced malignant tumors.
Patients with malignant ascites typically have a poor prognosis, with only 12 to 20 weeks of
survival. Currently, the standard treatments for malignant ascites are systemic chemotherapy,
which is ineffective in eradicating the disease and is associated with issues such as safety, short duration
of sustained high-level drug concentration in localised regions, and drug resistance.
Objective: To clarify the effect of Qigu Zhushui decoction on inhibiting malignant ascites in mice
and provide the experimental basis for further research.
Methods: The ascites model of liver cancer in mice was established by intraperitoneal injection of
the H22-H8D8 cell line of liver cancer. ELISA detected the content of CEA, VEGF and TNF-α in
ascites.
Results: Qigu Zhushui decoction combined with cisplatin group and Qigu Zhushui decoction highdose
group could significantly reduce the weight, abdominal circumference and ascites volume of
mice, and their survival days and survival rate were also greatly improved; The levels of CEA and
VEGF in the combination group decreased significantly, while the level of TNF-α increased; The
level of TNF-a in the high dose group of Qigu Zhushui decoction was significantly increased,
while the level of CEA and VEGF in the moderate dose group was decreased.
Conclusion: Qigu Zhushui decoction can reduce the malignant ascites in mice, and the combination
of Qigu Zhushui decoction and cisplatin has a significant anti-malignant ascites effect, which
can significantly prolong the survival time and improve the survival rate.
Graphical Abstract
[3]
Zhang, X.; Jia, Y. Advances in the clinical treatment of malignant ascites. J. Emerg Tradit Chin Med., 2008, 17(4), 536-1537.
[7]
Chongqi, W.; Chiping, W.; Yuying, S. The clinical value of 5-FU combined with cisplatin for hyperthermic intraperitoneal chemoinfusion in treating cancerous ascites. Chin. J. Med. Drug Appl., 2008, 2, 9-10.
[9]
Li, Z.; Zhang, L.; Li, L. Treatment of malignant ascites with hyperthermic perfusion chemotherapy and high-frequency hyperthermia. Med. J. West China., 2010, 22, 517-521.
[10]
Yu, X.; Li, X.; Zhou, J. The clinical study of intraperitoneal chemotherapy combined with whole body hyperthermia by using microwave on abdomen for treating malignant peritoneal effusion. J. Clin. Intern. Med., 2007, 24, 253-255.
[19]
Zhao, A.G.; Cai, Y.; Yang, J.K.; Zheng, J.; Shen, K.P. Effect of Chinese Jianpi herbs on prognosis of gastric cancer. World Chin. J. Digestology, 2005, 13(9), 1055-1058.
[21]
Zhou, L.; Zhang, S. Clinical observation of adjusted Wu Ling Decoction treating 70 patients with malignant ascites. J. Practical Chinese Intern. Med., 2010, 24, 7-711.
[27]
Xu, H.; Zhou, S. The significance of combined detection of CEA, CAl25, CAl53, ADA and Glu in the differential diagnosis of tuberculous and cancerous pleural ascites. Jiangxi Med. J., 2014, 49(5), 460-461.
[32]
Wang, S.; Zhu, Y. Appreciation of the detection of pleural, ascites and serum carcinoembryonic antigen in the differential diagnosis of benign and malignant pleural effusion and ascites. Lab. Med., 2007, 22(4), 448-450.
[34]
Yoshida, N.; Ikemoto, S.; Narita, K. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br. J. Cancer, 2002, 86(9), 1396-1400.
[35]
Ding, T.; Zhou, N.; Tuo, P. Determination of tumor necrosis factor alpha in the thorax and ascites and its clinical significance. Med. J. Chinese People’s Armed Police For., 2000, 11(5), 272.
[36]
Jia, Q.; Liang, X. The role of tumor necrosis factor in benign and malignant ascites. Beijing Med. J., 1999, 21(3), 169.
[38]
Ye, Q.L. On spleen governing transformation of dampness. Chinese J. Basic Med. Trad. Chinese Med., 2004, 10(11), 11-13.
Download PDF Flyer